Sign In
Buy RHHBY
$50.50
-1.41 (-2.72%)
At Close: Jul 13, 2026
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
12:36pm, Wednesday, 08'th Jul 2026
Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
02:46pm, Friday, 03'rd Jul 2026
RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus approved inhibitors.
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
01:50am, Thursday, 02'nd Jul 2026
Experimental drug, divarasib, showed meaningful improvements in both patients' overall survival and the time they survived without the disease worsening.
Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease
03:50pm, Tuesday, 30'th Jun 2026
Roche won FDA priority review for Enspryng in thyroid eye disease, with a decision date in October and phase III data backing the filing.
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
07:45am, Tuesday, 30'th Jun 2026
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip
04:07am, Monday, 29'th Jun 2026
Swiss pharma and diagnostics giant Roche on Monday launched its long-awaited Axelios gene sequencer, in a bid to challenge U.S. firm Illumina's leadership in next-generation sequencing.
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
01:00am, Monday, 29'th Jun 2026
AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise their workflows and explore a wider array of appl
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
03:26pm, Tuesday, 23'rd Jun 2026
Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.
U.S.-Iran deal will stick despite being a ‘bad, bad deal', says David Roche
12:15am, Friday, 19'th Jun 2026
Quantum Strategy's David Roche expects the US-Iran deal to hold, arguing both Washington and Tehran have strong incentives to keep Iranian oil flowing and avoid political disruption ahead of US midter
FDA Accepts Roche's Filing for Lunsumio VELO-Polivy in LBCL
01:50pm, Thursday, 18'th Jun 2026
FDA accepts RHHBY filing for Lunsumio VELO plus Polivy in relapsed or refractory LBCL as a potential chemotherapy-free treatment option.
FDA approves first generic version of Roche's flu drug
06:35pm, Wednesday, 17'th Jun 2026
The U.S. Food and Drug Administration approved the first generic version of Roche's Xofluza, a single-dose flu medicine for certain patients aged five years and older, the regulator said on Wedn
JAZZ's Zepzelca Fails to Meet Primary Goal in Lung Cancer Study
01:21pm, Monday, 15'th Jun 2026
Jazz Pharmaceuticals' Zepzelca fails a phase III lung cancer study, but strong first-line uptake and 2026 guidance remain unchanged.
Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer
03:15pm, Friday, 12'th Jun 2026
The new VENTANA PTEN (SP218) RxDx Assay fulfils an unmet medical need by helping clinicians identify patients with PTEN protein loss who may benefit from combination treatment with TRUQAP In prostate
Roche's Tecentriq Plus Chemo Gets FDA Priority Tag for Colon Cancer
10:47am, Thursday, 11'th Jun 2026
RHHBY wins FDA priority review for Tecentriq plus FOLFOX6 in stage III dMMR/MSI-H colon cancer, with a decision due in October 2026.
Nurix Therapeutics Deal With Roche Is Worth Betting On
09:48am, Thursday, 11'th Jun 2026
Recently, Nurix secured a partnership with Roche, which I believe has substantially derisked the stock as a whole. Similarly, this deal helps validate NRIX's bexobrutideg and its potential as a broade
